Diffuse large B-cell lymphoma: New targets and novel therapies Review
| Authors: | Cheson, B. D.; Nowakowski, G.; Salles, G. |
| Review Title: | Diffuse large B-cell lymphoma: New targets and novel therapies |
| Abstract: | Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies. © 2021, The Author(s). |
| Keywords: | lenalidomide; fatigue; neutropenia; review; hypertension; gene targeting; cancer immunotherapy; multiple cycle treatment; anemia; thrombocytopenia; deep vein thrombosis; kidney failure; asthenia; backache; dyspnea; febrile neutropenia; pneumonia; rash; lung embolism; hypokalemia; nonhodgkin lymphoma; urinary tract infection; chronic lymphatic leukemia; atrial fibrillation; congestive heart failure; cd19 antigen; upper respiratory tract infection; phase 2 clinical trial (topic); phase 1 clinical trial (topic); hypertransaminasemia; diffuse large b cell lymphoma; combination drug therapy; human; tafasitamab |
| Journal Title: | Blood Cancer Journal |
| Volume: | 11 |
| Issue: | 4 |
| ISSN: | 2044-5385 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2021-04-01 |
| Start Page: | 68 |
| Language: | English |
| DOI: | 10.1038/s41408-021-00456-w |
| PUBMED: | 33820908 |
| PROVIDER: | scopus |
| PMCID: | PMC8021545 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 May 2021 -- Source: Scopus |
